EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieVergleichsstudieOpen Access · CC BY-NC-ND 4.0

Aspirin Plus Rivaroxaban Versus Rivaroxaban Alone for the Prevention of Venous Stent Thrombosis Among Patients With Post-Thrombotic Syndrome: The Multicenter, Multinational, Randomized, Open-Label ARIVA Trial

Stefano Barco iD, Houman Jalaie, Tim Sebastian, Simon Wolf, Riccardo M Fumagalli iD, Michael Lichtenberg, Thomas Zeller iD, Christian Erbel, Oliver Schlager iD, Nils Kucher iD

Circulation · 25.03.2025 · 151 (12) · 835-846

DOI: 10.1161/circulationaha.124.073050 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Circulation, erschienen am 25.03.2025. Verfasst von Stefano Barco und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Angiology, University Hospital Zurich, University of Zurich, Switzerland (S.B., T.S., S.W., R.M.F., N.K.). Hauptthemen laut MEDLINE: Rivaroxaban, Postthrombotic Syndrome, Aspirin, Stents. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bayer AG, BD Interventional, BD Switzerland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: In patients with post-thrombotic syndrome, stent recanalization of iliofemoral veins or the inferior vena cava can restore venous patency and improve functional outcomes. The risk of stent thrombosis is particularly increased during the first 6 months after intervention. The ARIVA trial (Aspirin Plus Rivaroxaban Versus Rivaroxaban Alone for the Prevention of Venous Stent Thrombosis in Patients With PTS) tested whether 100 mg of daily aspirin plus 20 mg of rivaroxaban is superior to 20 mg of rivaroxaban alone to prevent stent thrombosis within 6 months after stent placement for post-thrombotic syndrome. METHODS: In this multinational, academic, open-label, independently adjudicated trial, patients with a Villalta score >4 points and a stenosis or occlusion of the inferior vena cava, iliac veins, or common femoral vein successfully treated with venous stent placement were randomized in a 1:1 fashion to the study groups. Key exclusion criteria included 75 years of age, contraindications to anticoagulant use, or acute venous thrombosis

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RivaroxabanPostthrombotic SyndromeAspirinStentsFactor Xa InhibitorsVenous ThrombosisPlatelet Aggregation InhibitorsHumansMaleFemaleMiddle AgedAgedAdultDrug Therapy, CombinationTreatment Outcome

Stichwörter der Autor:innen

aspirinendovascular procedurespost-thrombotic syndromerivaroxabanthrombosis

Substanzen

RivaroxabanAspirinFactor Xa InhibitorsPlatelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Department of Angiology, University Hospital Zurich, University of Zurich, Switzerland (S.B., T.S., S.W., R.M.F., N.K.).
  • Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg University Mainz, Germany (S.B.).
  • Clinic of Vascular and Endovascular Surgery, RWTH Aachen University Hospital, Germany (H.J.).
  • Department of Angiology, Klinikum Hochsauerland, Arnsberg, Germany (M.L.).
  • Department of Cardiology and Angiology, University Heart Center Freiburg-Bad Krozingen, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Germany (T.Z.).
  • Department of Cardiology, Angiology and Pneumology, Heidelberg University Hospital, Germany (C.E.).

ORCID-Profile: Stefano Barco, Riccardo M Fumagalli, Thomas Zeller, Oliver Schlager, Nils Kucher

Förderung

  • Bayer AG
  • BD Interventional
  • BD Switzerland
  • Bentley InnoMed Gmbh
  • Medtronic
  • University Hospital Zurich

Zitieren

APA

Barco, S., Jalaie, H., Sebastian, T., Wolf, S., Fumagalli, R. M., Lichtenberg, M., Zeller, T., Erbel, C., Schlager, O., & Kucher, N. (2025). Aspirin Plus Rivaroxaban Versus Rivaroxaban Alone for the Prevention of Venous Stent Thrombosis Among Patients With Post-Thrombotic Syndrome: The Multicenter, Multinational, Randomized, Open-Label ARIVA Trial. Circulation, 151(12), 835-846. https://doi.org/10.1161/circulationaha.124.073050

Vancouver

Barco S, Jalaie H, Sebastian T, Wolf S, Fumagalli RM, Lichtenberg M, et al. Aspirin Plus Rivaroxaban Versus Rivaroxaban Alone for the Prevention of Venous Stent Thrombosis Among Patients With Post-Thrombotic Syndrome: The Multicenter, Multinational, Randomized, Open-Label ARIVA Trial. Circulation. 2025;151(12):835-846. doi:10.1161/circulationaha.124.073050

BibTeX
@article{Barco2025,
  author = {Barco, Stefano and Jalaie, Houman and Sebastian, Tim and Wolf, Simon and Fumagalli, Riccardo M and Lichtenberg, Michael and Zeller, Thomas and Erbel, Christian and Schlager, Oliver and Kucher, Nils},
  title = {Aspirin Plus Rivaroxaban Versus Rivaroxaban Alone for the Prevention of Venous Stent Thrombosis Among Patients With Post-Thrombotic Syndrome: The Multicenter, Multinational, Randomized, Open-Label ARIVA Trial},
  journal = {Circulation},
  year = {2025},
  volume = {151},
  number = {12},
  pages = {835--846},
  doi = {10.1161/circulationaha.124.073050}
}
Kostenlos starten →